Table of Contents
ISRN AIDS
Volume 2012, Article ID 621565, 8 pages
http://dx.doi.org/10.5402/2012/621565
Clinical Study

Diabetes and Hypertension among Patients Receiving Antiretroviral Treatment Since 1998 in Senegal: Prevalence and Associated Factors

1Centre Régional de Recherche et de Formation à la Prise en charge du VIH/sida et maladies associées (CRCF), Université Cheikh Anta Diop (UCAD), BP 45690, Dakar, Senegal
2Service des Maladies Infectieuses, Centre Hospitalier Universitaire (CHU) de Fann, BP 5035, Dakar, Senegal
3UMI 233, Institut de Recherche pour le Développement (IRD), Université de Montpellier 1, BP 64501, 34394 Montpellier Cedex 5, Montpellier, France
4Service de Médecine Boufflers, Hôpital Principal de Dakar, BP 3006, Dakar, Senegal
5Centre de Traitement Ambulatoire (CTA), CHU de Fann, BP 16760, Dakar, Senegal

Received 28 September 2012; Accepted 30 October 2012

Academic Editors: B. Joos and A. B. Williams

Copyright © 2012 Assane Diouf et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. OMS, ONUSIDA, UNICEF, “UNICEF. La riposte mondiale au VIH/sida: rapport de situation 2011,” http://www.who.int/hiv/pub/progress_report2011/hiv_report_summary_2011_fr.pdf.
  2. République du Sénégal, “Conseil National de Lutte contre le Sida (CNLS), Programme Commun des Nations Unies sur le VIH/sida (ONUSIDA),” Rapport De Situation Sur La Riposte NationaLe À L’Épidémie De VIH/Sida, SénégaL 2010–2011, 2012. View at Google Scholar
  3. F. J. Palella Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten et al., “Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators,” The New England Journal of Medicine, vol. 338, no. 13, pp. 853–860, 1998. View at Google Scholar
  4. S. G. Deeks, “Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy,” Topics in HIV Medicine, vol. 17, no. 4, pp. 118–123, 2009. View at Google Scholar · View at Scopus
  5. A. C. Justice, “HIV and aging: time for a new paradigm,” Current HIV/AIDS Reports, vol. 7, no. 2, pp. 69–76, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Antiretroviral Therapy Cohort Collaboration, “Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies,” The Lancet, vol. 372, no. 9635, pp. 293–299, 2008. View at Google Scholar
  7. M. May, M. Gompels, V. Delpech, K. Porter, F. Post, M. Johnson et al., “Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort, (UK CHIC) Study,” British Medical Journal, vol. 343, Article ID d6016, 2011. View at Google Scholar
  8. L. Cockerham, R. Scherzer, A. Zolopa et al., “Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent haart Era,” Journal of Acquired Immune Deficiency Syndromes, vol. 53, no. 1, pp. 102–106, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Egger, “Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries,” International Journal of Epidemiology, vol. 38, no. 6, pp. 1624–1633, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. N. Lohse, A. B. E. Hansen, G. Pedersen et al., “Survival of persons with and without HIV infection in Denmark, 1995–2005,” Annals of Internal Medicine, vol. 146, no. 2, pp. 87–95, 2007. View at Google Scholar · View at Scopus
  11. R. Weber, C. A. Sabin, N. Friis-Møller, P. Reiss, W. M. El-Sadr, O. Kirk et al., “Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study,” Archives of Internal Medicine, vol. 166, no. 15, pp. 1632–1641, 2006. View at Google Scholar
  12. A. C. Justice, “Prioritizing primary care in HIV: comorbidity, toxicity, and demography,” Topics in HIV Medicine, vol. 14, no. 5, pp. 159–163, 2006. View at Google Scholar · View at Scopus
  13. J. E. Sackoff, D. B. Hanna, M. R. Pfeiffer, and L. V. Torian, “Causes of death among persons with aids in the era of highly active antiretroviral therapy: New York City,” Annals of Internal Medicine, vol. 145, no. 6, pp. 397–406, 2006. View at Google Scholar · View at Scopus
  14. A. N. Phillips, J. Neaton, and J. D. Lundgren, “The role of HIV in serious diseases other than AIDS,” AIDS, vol. 22, no. 18, pp. 2409–2418, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Herida, M. Mary-Krause, R. Kaphan et al., “Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients,” Journal of Clinical Oncology, vol. 21, no. 18, pp. 3447–3453, 2003. View at Google Scholar
  16. G. Guaraldi, G. Orlando, S. Zona, M. Menozzi, F. Carli, E. Garlassi et al., “Premature age-related comorbidities among HIV-infected persons compared with the general population,” Clinical Infectious Diseases, vol. 53, no. 11, pp. 1120–1126, 2011. View at Google Scholar
  17. P. W. Hunt, J. N. Martin, E. Sinclair et al., “T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency vires-infected patients with sustained viral suppression during antiretroviral therapy,” Journal of Infectious Diseases, vol. 187, no. 10, pp. 1534–1543, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. P. W. Hunt, J. Brenchley, E. Sinclair et al., “Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy,” Journal of Infectious Diseases, vol. 197, no. 1, pp. 126–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. M. Brenchley, D. A. Price, T. W. Schacker et al., “Microbial translocation is a cause of systemic immune activation in chronic HIV infection,” Nature Medicine, vol. 12, no. 12, pp. 1365–1371, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Palmer, F. Maldarelli, A. Wiegand et al., “Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 10, pp. 3879–3884, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. R. Stacey, P. J. Norris, L. Qin et al., “Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections,” Journal of Virology, vol. 83, no. 8, pp. 3719–3733, 2009. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Calmy, B. Hirschel, D. A. Cooper, and A. Carr, “Clinical update: adverse effects of antiretroviral therapy,” The Lancet, vol. 370, no. 9581, pp. 12–14, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Brinkman, H. J. M. Ter Hofstede, D. M. Burger, J. A. M. Smeitink, and P. P. Koopmans, “Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway,” AIDS, vol. 12, no. 14, pp. 1735–1744, 1998. View at Google Scholar · View at Scopus
  24. S. W. Worm, C. Sabin, R. Weber et al., “Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of Anti-HIV Drugs (D:A:D) Study,” Journal of Infectious Diseases, vol. 201, no. 3, pp. 318–330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. The SMART/INSIGHT and the D:A:D Study Groups, “Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients,” AIDS, vol. 22, no. 14, pp. F17–F24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Mocroft, O. Kirk, P. Reiss et al., “Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients,” AIDS, vol. 24, no. 11, pp. 1667–1678, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. S. G. Deeks and A. N. Phillips, “HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity,” British Medical Journal, vol. 338, Article ID a3172, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Bisson, R. Gross, V. Miller, I. Weller, and A. Walker, “Monitoring of long-term toxicities of HIV treatments: an international perspective,” AIDS, vol. 17, no. 17, pp. 2407–2417, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. J. L. Goulet, S. L. Fultz, D. Rimland et al., “Do patterns of comorbidity vary by HIV status, age, and HIV severity?” Clinical Infectious Diseases, vol. 45, no. 12, pp. 1593–1601, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. R. E. Gress and S. G. Deeks, “Reduced thymus activity and infection prematurely age the immune system,” Journal of Clinical Investigation, vol. 119, no. 10, pp. 2884–2887, 2009. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Kirk and M. B. Goetz, “Human immunodeficiency virus in an aging population, a complication of success,” Journal of the American Geriatrics Society, vol. 57, no. 11, pp. 2129–2138, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. D. M. Zannou, L. Denoeud, K. Lacombe et al., “Incidence of lipodystrophy and metabolic disorders in patients starting non-nucleoside reverse transcriptase inhibitors in Benin,” Antiviral Therapy, vol. 14, no. 3, pp. 371–380, 2009. View at Google Scholar · View at Scopus
  33. H. Julius, D. Basu, E. Ricci et al., “The burden of metabolic diseases amongst HIV positive patients on HAART attending the Johannesburg hospital,” Current HIV Research, vol. 9, no. 4, pp. 247–252, 2011. View at Google Scholar · View at Scopus
  34. P. Cahn, O. Leite, A. Rosales et al., “Metabolic profile and cardiovascular risk factors among Latin American HIV-infected patients receiving HAART,” Brazilian Journal of Infectious Diseases, vol. 14, no. 2, pp. 158–166, 2010. View at Google Scholar · View at Scopus
  35. R. Bedimo, A. O. Westfall, M. Mugavero, H. Drechsler, N. Khanna, and M. Saag, “Hepatitis C virus coinfection and the risk of cardiovascular disease among HIV-infected patients,” HIV Medicine, vol. 11, no. 7, pp. 462–468, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. P. C. Tien, M. F. Schneider, S. R. Cole et al., “Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV Study,” AIDS, vol. 21, no. 13, pp. 1739–1745, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. T. T. Brown, S. R. Cole, X. Li et al., “Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study,” Archives of Internal Medicine, vol. 165, no. 10, pp. 1179–1184, 2005. View at Publisher · View at Google Scholar · View at Scopus
  38. E. F. Da Silva, K. C. Bassichetto, and D. S. Lewi, “Lipid profile, cardiovascular risk factors and metabolic syndrome in a group of AIDS patients,” Arquivos Brasileiros de Cardiologia, vol. 93, no. 2, pp. 113–118, 2009. View at Publisher · View at Google Scholar · View at Scopus
  39. A. A. Howard, M. Floris-Moore, J. H. Arnsten et al., “Disorders of glucose metabolism among HIV-infected women,” Clinical Infectious Diseases, vol. 40, no. 10, pp. 1492–1499, 2005. View at Publisher · View at Google Scholar · View at Scopus
  40. M. I. González-Tomé, J. T. Ramos Amador, S. Guillen et al., “Gestational diabetes mellitus in a cohort of HIV-1 infected women,” HIV Medicine, vol. 9, no. 10, pp. 868–874, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. H. Wand, A. Calmy, D. L. Carey et al., “Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection,” AIDS, vol. 21, no. 18, pp. 2445–2453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. M. K. Jain, C. Aragaki, L. Fischbach et al., “Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors,” HIV Medicine, vol. 8, no. 8, pp. 491–497, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. B. Ledergerber, H. Furrer, M. Rickenbach et al., “Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study,” Clinical Infectious Diseases, vol. 45, no. 1, pp. 111–119, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. A. A. Howard, M. Floris-Moore, Y. Lo, J. H. Arnsten, N. Fleischer, and R. S. Klein, “Abnormal glucose metabolism among older men with or at risk of HIV infection,” HIV Medicine, vol. 7, no. 6, pp. 389–396, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. A. A. Butt, S. L. Fultz, C. K. Kwoh, D. Kelley, M. Skanderson, and A. C. Justice, “Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection,” Hepatology, vol. 40, no. 1, pp. 115–119, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. A. A. Howard, R. S. Klein, and E. E. Schoenbaum, “Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users,” Clinical Infectious Diseases, vol. 36, no. 10, pp. 1318–1323, 2003. View at Publisher · View at Google Scholar · View at Scopus
  47. M. Savès, F. Raffi, J. Capeau et al., “Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 34, no. 10, pp. 1396–1405, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. S. De Wit, C. A. Sabin, R. Weber et al., “Incidence and risk factors for new-onset diabetes in HIV-infected patients,” Diabetes Care, vol. 31, no. 6, pp. 1224–1229, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. J. Capeau, V. Bouteloup, C. Katlama et al., “Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment,” AIDS, vol. 26, no. 3, pp. 303–314, 2012. View at Google Scholar
  50. E. R. de Arruda, H. R. Lacerda, L. C. R. V. Moura et al., “Risk factors related to hypertension among patients in a cohort living with HIV/AIDS,” Brazilian Journal of Infectious Diseases, vol. 14, no. 3, pp. 281–287, 2010. View at Google Scholar · View at Scopus
  51. B. Mothe, I. Perez, P. Domingo et al., “HIV-1 infection in subjects older than 70: a multicenter cross-sectional assessment in Catalonia, Spain,” Current HIV Research, vol. 7, no. 6, pp. 597–600, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. M. Baekken, I. Os, L. Sandvik, and O. Oektedalen, “Hypertension in an urban HIV-positive population compared with the general population: influence of combination antiretroviral therapy,” Journal of Hypertension, vol. 26, no. 11, pp. 2126–2133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Palacios Muñoz, J. Santos, A. García et al., “Impact of highly active antiretroviral therapy on blood pressure in HIV-infected patients. A prospective study in a cohort of naive patients,” HIV Medicine, vol. 7, no. 1, pp. 10–15, 2006. View at Publisher · View at Google Scholar · View at Scopus
  54. B. M. Bergersen, L. Sandvik, O. Dunlop, K. Birkeland, and J. N. Bruun, “Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-Naïve and HIV-negative controls: results from a Norwegian Study of 721 patients,” European Journal of Clinical Microbiology and Infectious Diseases, vol. 22, no. 12, pp. 731–736, 2003. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Gazzaruso, R. Bruno, A. Garzaniti et al., “Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome,” Journal of Hypertension, vol. 21, no. 7, pp. 1377–1382, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. A. G. Coloma Conde, M. Álvarez Albarrán, A. Roca-Cusachs Coll, P. Domingo Pedrol, and M. Puig Campmany, “Prevalence of arterial hypertension and lipid profile in HIV patients,” Medicina Clinica, vol. 131, no. 18, pp. 681–684, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. J. M. Grandominico and C. J. Fichtenbaum, “Short-term effect of HAART on blood pressure in HIV-infected individuals,” HIV Clinical Trials, vol. 9, no. 1, pp. 52–60, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. H. M. Crane, S. E. Van Rompaey, and M. M. Kitahata, “Antiretroviral medications associated with elevated blood pressure among patients receiving highly active antiretroviral therapy,” AIDS, vol. 20, no. 7, pp. 1019–1026, 2006. View at Publisher · View at Google Scholar · View at Scopus
  59. R. Thiébaut, W. M. El-Sadr, N. Friis-Møller et al., “Predictors of hypertension and changes of blood pressure in HIV-infected patients,” Antiviral Therapy, vol. 10, no. 7, pp. 811–823, 2005. View at Google Scholar · View at Scopus
  60. E. C. Seaberg, A. Muñoz, M. Lu et al., “Association between highly active antiretroviral therapy and hypertension in a large cohort of men followed from 1984 to 2003,” AIDS, vol. 19, no. 9, pp. 953–960, 2005. View at Google Scholar · View at Scopus
  61. D. C. Chow, S. A. Souza, R. Chen et al., “Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy,” HIV Clinical Trials, vol. 4, no. 6, pp. 411–416, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. H. M. Crane, C. Grunfeld, R. D. Harrington, and M. M. Kitahata, “Lipoatrophy and lipohypertrophy are independently associated with hypertension,” HIV Medicine, vol. 10, no. 8, pp. 496–503, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. A. M. Cattelan, M. Trevenzoli, A. Naso, F. Meneghetti, and P. Cadrobbi, “Severe hypertension and renal atrophy associated with indinavir,” Clinical Infectious Diseases, vol. 30, no. 3, pp. 619–621, 2000. View at Publisher · View at Google Scholar · View at Scopus
  64. A. Kane, S. A. Ba, M. Sarr et al., “Arterial hypertension in Senegal: epidemiological aspects, clinical features, and therapeutic management problems,” Dakar Médical, vol. 40, no. 2, pp. 157–161, 1995. View at Google Scholar · View at Scopus
  65. S. B. Gning, M. Thiam, F. Fall, K. Ba-Fall, P. S. Mbaye, and L. Fourcade, “Le diabète sucré en Afrique subsaharienne: aspects épidémiologiques, difficultés de prise en charge,” Médecine Tropicale, vol. 67, pp. 607–611, 2007. View at Google Scholar
  66. M. N. Mbaye, K. Niang, A. Sarr, A. Mbaye, D. Diedhiou, M. D. Ndao et al., “Aspects épidémiologiques du diabète au Sénégal : résultats d’une enquête sur les facteurs de risque cardiovasculaire dans la ville de Saint-Louis,” Médecine des Maladies Métaboliques, vol. 6, pp. 659–664, 2011. View at Google Scholar
  67. S. Yusuf, S. Hawken, and S. Ounpuu, “Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study,” The Lancet, vol. 364, no. 9450, p. 2020, 2004. View at Publisher · View at Google Scholar · View at Scopus
  68. X. Duval, G. Baron, D. Garelik et al., “Living with HIV, antiretroviral treatment experience and tobacco smoking: results from a multisite cross-sectional study,” Antiviral Therapy, vol. 13, no. 3, pp. 389–397, 2008. View at Google Scholar · View at Scopus
  69. R. J. Devlin and J. A. Henry, “Clinical review: major consequences of illicit drug consumption,” Critical Care, vol. 12, article 202, 2008. View at Google Scholar · View at Scopus
  70. C. Lewden, T. May, E. Rosenthal et al., “Changes in causes of death among adults infected by HIV between 2000 and 2005: the “mortalité 2000 and 2005” surveys (ANRS EN19 and mortavic),” Journal of Acquired Immune Deficiency Syndromes, vol. 48, no. 5, pp. 590–598, 2008. View at Publisher · View at Google Scholar · View at Scopus